First Step
EU Readiness Assessment
Entering the European market is not a second FDA submission. In one complimentary 60-minute session, a senior AzurBio advisor helps you identify the early decisions that can shape your cost, timeline, and odds at review, while your development program can still be shaped.
No obligation. Just an expert perspective on your program.
One application → 30 EU/EEA countries · €200K – €1M+ in potential SME fee savings
What does the 60 minutes cover
- 1 – Your current EU readiness
A senior-level read of your current position from an EU regulatory perspective. - 2 – Your most critical next steps
The three actions that matter most for your specific situation, ranked by urgency and impact. - 3 – The EU path ahead
A practical view of what European authorization will require, what to anticipate, and which decisions should not wait.
Who this is for
Built for US and international biotechs developing their first medicine and considering Europe as their next regulatory frontier. If Europe is on your next step, this assessment is for you.